AFL atrial flutter AH arterial hypertension ANS autonomic nervous system APD action
potential duration ARREST-AF Aggressive Risk Factor Reduction Study for Atrial Fibrillation …

Члены Рабочей группы подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Рабочей …

clinical guidelines, atrial fibrillation, ischemic stroke, anticoagulant therapy, vitamin K
antagonists, direct oral anticoagulants, triple antiplatelet therapy, rhythm control, electrical …

Background Catheter ablation of atrial fibrillation is typically performed with uninterrupted
anticoagulation with warfarin or interrupted non–vitamin K antagonist oral anticoagulant …

Aims VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and
vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) …

Atrial fibrillation (AF) is the most common sustained arrhythmia, causing a 2-fold increase in
mortality and a 5-fold increase in stroke. The Asian population is rapidly aging, and in 2050 …

Since the advent of the non-vitamin K antagonist oral anticoagulant (NOAC) agents, which
act as direct thrombin inhibitors or inhibitors of Factor Xa, clinicians are provided with …

Anticoagulation for Ablation of Atrial Fibrillation Introduction Appropriate activated clotting
time (ACT) during catheter ablation of atrial fibrillation (CA‐AF) is essential to minimize …

Abstract Background New oral anticoagulants (NOACs) have been shown to be comparable
to warfarin in patients with non-valvular atrial fibrillation (AF). This meta-analysis was …

Background Non–vitamin K antagonist oral anticoagulants are used to prevent
thromboembolism in patients with atrial fibrillation. The T‐TAS “Total Thrombus‐formation …